Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma ... although the picture may not be ...

A type of skin cancer, which forms in the middle and outer layer of the skin. It causes red nodules, scaly, red patches on lips or inside the mouth, , open sores, or wartlike sore on or in the ...

Sanofi said the results are strong enough to support a new indication in the US and EU for Libtayo, a PD-1 inhibitor that is already FDA-approved in advanced cutaneous squamous cell carcinoma.

There are three types of skin cancer: melanoma, basal cell carcinoma, and squamous cell carcinoma. About 20% of people in the US will eventually develop one of these three types of skin cancer.